What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
DOI:
https://doi.org/10.15277/bjd.2017.136References
The CANVAS Program (CANagliflozin cardioVascular Assessment Study). The slide set used at the presentation of the CANVAS study results on June 12th 2017 during the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA. http://www.georgeinstitute.org/sites/default/files/canvas-study-results-ada-2017.pdf (accessed 3 July 2017)
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017. https://doi.org/10.1056/NEJMoa1611925. [Epub ahead of print]
Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME™: the optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis 2015;15:151-4. http://dx.doi.org/10.15277/bjdvd.2015.045
Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? Br J Diabetes 2016;16:103-06. http://dx.doi.org/10.15277/bjd.2016.096
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care 2017;40(7):813-20. https://doi.org/10.2337/dc16-2736.
Gautam A, Agrawal PK, Prakash P, Hazra DK. Pioglitazone associated pedal edema resolved by adding sodium glucose co-transporter 2 in-hibitor. ADA 76th Scientific Sessions 2016. Late Breaking Poster Session, Poster 140-LB. Abstract available at http://www.abstractsonline.com/pp8/#!/4008/presentation/44543 (accessed 27 July 2017)
Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015; 17:268-75. http://dx.doi.org/10.1111/dom.12417
AstraZeneca. Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk. Press release 23 May 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html (accessed 7 July 2017)
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. http://dx.doi.org/10.1056/NEJMoa1504720
Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1(2):140-51. https://doi.org/10.1016/S2213-8587(13)70050-0. Epub 2013 Aug 13.
Bailey CJ. CANVAS Program Independent Commentary. The slide set used for the independent commentary after the presentation of the CANVAS study results on June 12th 2017 during the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA. http://www.georgeinstitute.org/sites/default/files/canvas-independent-commentary-ada.pdf (accessed 3 July 2017)
European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. 20 April 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp&mid=WC0b01ac05805c516f (accessed 3 July 2017)
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
